139 related articles for article (PubMed ID: 24823463)
21. Does addition of temozolomide to whole brain radiotherapy improve outcome in patients with brain metastases?
Erridge SC; Gregor A
Nat Clin Pract Oncol; 2005 Apr; 2(4):194-5. PubMed ID: 16264933
[No Abstract] [Full Text] [Related]
22. Intracerebral hemorrhage secondary to thrombocytopenia in a patient treated with temozolomide.
Sure D; Dunn I; Norden A; Anderson WS
Clin Neurol Neurosurg; 2010 Oct; 112(8):741-2. PubMed ID: 20434832
[TBL] [Abstract][Full Text] [Related]
23. Treatment of invasive silent somatotroph pituitary adenoma with temozolomide. Report of a case and review of the literature.
Ghazi AA; Rotondo F; Kovacs K; Amirbaigloo A; Syro LV; Fathalla H; Di Ieva A; Cusimano MD
Endocr Pathol; 2015 May; 26(2):135-9. PubMed ID: 25716461
[TBL] [Abstract][Full Text] [Related]
24. Non-uniform response to temozolomide therapy in a pituitary gonadotroph adenoma.
Ersen A; Syro LV; Penagos L; Uribe H; Scheithauer BW; Ortiz LD; Rotondo F; Horvath E; Kovacs K
Can J Neurol Sci; 2012 Sep; 39(5):683-5. PubMed ID: 23066557
[No Abstract] [Full Text] [Related]
25. Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies.
Raverot G; Jouanneau E; Trouillas J
Eur J Endocrinol; 2014 Apr; 170(4):R121-32. PubMed ID: 24431196
[TBL] [Abstract][Full Text] [Related]
26. Complete response of multiple melanoma brain metastases after treatment with temozolomide.
Dvorak J; Melichar B; Zizka J; Hadzi-Nikolov D; Petera J
Onkologie; 2004 Apr; 27(2):171-4. PubMed ID: 15138351
[TBL] [Abstract][Full Text] [Related]
27. Treatment of brain metastases from melanoma.
Legha SS
J Clin Oncol; 2005 May; 23(13):3155; author reply 3155-6. PubMed ID: 15860880
[No Abstract] [Full Text] [Related]
28. Effect of temozolomide in a patient with recurring oncocytic gonadotrophic pituitary adenoma.
Syro LV; Scheithauer BW; Ortiz LD; Fadul CE; Horvath E; Rotondo F; Kovacs K
Hormones (Athens); 2009; 8(4):303-6. PubMed ID: 20045804
[TBL] [Abstract][Full Text] [Related]
29. Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center.
Ceccato F; Lombardi G; Manara R; Emanuelli E; Denaro L; Milanese L; Gardiman MP; Bertorelle R; Scanarini M; D'Avella D; Occhi G; Boscaro M; Zagonel V; Scaroni C
J Neurooncol; 2015 Mar; 122(1):189-96. PubMed ID: 25555563
[TBL] [Abstract][Full Text] [Related]
30. Relapsing, remitting hypercortisolism in Cushing's disease due to intratumoral hemorrhages in pituitary microadenoma.
Marko NF; Hamrahian AH; Hatipoglu B; Weil RJ
J Clin Neurosci; 2013 May; 20(5):753-6. PubMed ID: 23352667
[TBL] [Abstract][Full Text] [Related]
31. Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
Bengtsson D; Schrøder HD; Andersen M; Maiter D; Berinder K; Feldt Rasmussen U; Rasmussen ÅK; Johannsson G; Hoybye C; van der Lely AJ; Petersson M; Ragnarsson O; Burman P
J Clin Endocrinol Metab; 2015 Apr; 100(4):1689-98. PubMed ID: 25646794
[TBL] [Abstract][Full Text] [Related]
32. Anti-VEGF therapy in pituitary carcinoma.
Ortiz LD; Syro LV; Scheithauer BW; Ersen A; Uribe H; Fadul CE; Rotondo F; Horvath E; Kovacs K
Pituitary; 2012 Sep; 15(3):445-9. PubMed ID: 21918831
[TBL] [Abstract][Full Text] [Related]
33. Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas.
Losa M; Bogazzi F; Cannavo S; Ceccato F; Curtò L; De Marinis L; Iacovazzo D; Lombardi G; Mantovani G; Mazza E; Minniti G; Nizzoli M; Reni M; Scaroni C
J Neurooncol; 2016 Feb; 126(3):519-25. PubMed ID: 26614517
[TBL] [Abstract][Full Text] [Related]
34. Treatment of pituitary neoplasms with temozolomide: A review.
Marucci G
Cancer; 2011 Sep; 117(17):4101-2; author reply 4102. PubMed ID: 21387270
[No Abstract] [Full Text] [Related]
35. Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
Losa M; Mazza E; Terreni MR; McCormack A; Gill AJ; Motta M; Cangi MG; Talarico A; Mortini P; Reni M
Eur J Endocrinol; 2010 Dec; 163(6):843-51. PubMed ID: 20870708
[TBL] [Abstract][Full Text] [Related]
36. Intracranial metastatic esthesioneuroblastoma responsive to temozolomide.
Wick W; Wick A; Küker W; Dichgans J; Weller M
J Neurooncol; 2004 Oct; 70(1):73-5. PubMed ID: 15527110
[TBL] [Abstract][Full Text] [Related]
37. Temozolomide in aggressive pituitary adenomas and carcinomas.
Ortiz LD; Syro LV; Scheithauer BW; Rotondo F; Uribe H; Fadul CE; Horvath E; Kovacs K
Clinics (Sao Paulo); 2012; 67 Suppl 1(Suppl 1):119-23. PubMed ID: 22584716
[TBL] [Abstract][Full Text] [Related]
38. [Complete response of cerebral metastasic melanoma after a combined treatment of radiotherapy and temozolomide].
Conill C; Puig S; Toscas I; Castel T
Med Clin (Barc); 2002 Nov; 119(19):758-9. PubMed ID: 12487980
[No Abstract] [Full Text] [Related]
39. Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.
McCormack AI; Wass JA; Grossman AB
Eur J Clin Invest; 2011 Oct; 41(10):1133-48. PubMed ID: 21496012
[TBL] [Abstract][Full Text] [Related]
40. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study.
Agarwala SS; Kirkwood JM; Gore M; Dreno B; Thatcher N; Czarnetski B; Atkins M; Buzaid A; Skarlos D; Rankin EM
J Clin Oncol; 2004 Jun; 22(11):2101-7. PubMed ID: 15169796
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]